Open AccessLong‐term outcomes of switching to fixed‐dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3‐year results of the BICOMBO study
Author(s) -
Martínez E,
Arranz JA,
Podzamczer D,
Lonca M,
Sanz J,
Barragán P,
Knobel H,
Ribera E,
Gutierrez F,
Valero S,
Clotet B,
Dalmau D,
Segura F,
Arribas JR,
Barrufet P,
Santos I,
Payeras A,
Lazzari E,
Pich J,
Gatell J
Publication year - 2010
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.1186/1758-2652-13-s4-p43
Subject(s) - medicine , lamivudine , discontinuation , abacavir , emtricitabine , adverse effect , tenofovir , viral load , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , hepatitis b virus , virus
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK